Led · Series B · Jul 2026

Qureight provides two integrated products for pharmaceutical clinical trials: Workflow, which speeds imaging decision turnaround from about two weeks to 48 hours, and AI Lung, which constructs detailed models of airways and blood vessels from chest scans. The company has built a general-purpose foundation model of the chest that enables development of disease-specific deep learning models in one to two months. Qureight is running global clinical trials with partners including AstraZeneca, Bristol Myers Squibb, and several biotech firms. Founded in 2018, the company combines clinical leadership—co-founder and CEO Dr Muhunthan Thillai continues clinical work—with a senior technical team recruited from industry and academia. Financially, Qureight has raised a £1.5 million seed in 2022 and the recent $20 million Series B to support lab build-out, therapeutic-area expansion, and headcount growth.

Participated · Series D · Jun 2026

Isar Aerospace develops the Spectrum small-satellite orbital launch vehicle and positions itself as a commercial launch provider. Founded in 2018 in Munich, the company operates a 40,000 square metre production facility in Parsdorf designed to produce up to 40 Spectrum rockets per year, with vehicles three through seven already in production. Its launch manifest is booked through 2028 with customers including ESA, NOSA, ElevationSpace and Astroscale, and it operates from Andøya with a second launch site secured in Canada (Spaceport Nova Scotia). The company has pursued industrial partnerships such as a cooperation agreement with TKMS and received institutional backing including a €65 million NATO Innovation Fund extension in 2024. Spectrum’s qualification flight window opened June 15–21 after an initial March 30, 2025 launch that lasted under 30 seconds and several subsequent aborted attempts; reaching orbit is a milestone that would establish Isar as a commercial provider. With the recent financing, total funding across equity and debt is about €870 million, and capital is being directed at production scale-up, launch infrastructure, and executing its booked manifest.

Led · Series A · Jun 2026

IMU Biosciences combines high-fidelity multi-omic analysis with proprietary machine learning to generate detailed immune profiles, claiming the world’s largest immune dataset. Its platform can analyze more than 100 million immune data points from a single blood sample and the company expects its dataset to scale to over 25,000 individuals by 2026. IMU is applying its platform across immune-mediated diseases and therapeutic areas, including transplantation and immuno-oncology, and is advancing clinical initiatives such as Stem Cell and Solid Organ Transplant programs and the MANIFEST cancer immunotherapy consortium. The company plans to use recent funding to expand operations and strengthen clinical infrastructure to support these programs. IMU was founded by experimental immunologists and computational biologists with roots at the Francis Crick Institute and King’s College London and has now raised a total of $60 million to date.

Participated · Series B · Apr 2026

Manna Air Delivery operates a regulated consumer drone delivery network using proprietary software and hardware to deliver everyday items in minutes to suburban customers. The company has completed more than 250,000 regulated commercial UAV flights, holds a Gold Standard Light UAS Operator Certificate under EASA, and employs over 170 staff. Manna reports deliveries in under three minutes, an NPS of 86, and claims CO2 emissions reductions of up to 85% versus road-based delivery. It currently operates in Ireland, Finland and Texas and has partnerships with platforms including Uber, Deliveroo, Just Eat and DoorDash. Founded in 2019, Manna positions itself as an infrastructure provider for instant logistics and plans to scale to as many as 40 bases in the United States with the new funding.

Participated · Equity · Feb 2026

SatVu is a UK-based thermal Earth-observation company that captures 3.5-metre resolution infrared imagery day and night to provide intelligence on buildings, industrial sites, and other strategic assets. Its data helps government, defence, and industrial customers detect heat signatures linked to operational changes, assess readiness, and monitor climate-related emissions. The company currently operates a single demonstration satellite but is transitioning to a multi-satellite constellation; two new satellites are slated for launch in 2026 and a further three are already under contract. This expanded fleet will boost revisit frequency, enabling near-continuous monitoring of global activity. Beyond defence, SatVu’s imagery supports sectors such as steel, cement, data centres, oil & gas, and solar energy. Following the latest raise, SatVu has secured £60 million in total equity funding to date, providing capital for constellation build-out and commercial scaling.